NMRA 511
Alternative Names: BTRX-323511; NMRA 323511; NMRA-511Latest Information Update: 28 Nov 2024
At a glance
- Originator BlackThorn Therapeutics
- Developer Neumora Therapeutics
- Class Antidementias; Anxiolytics; Neuroprotectants; Small molecules
- Mechanism of Action Vasopressin 1a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Agitation
- No development reported Anxiety disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Anxiety-disorders in USA
- 09 Jul 2024 Phase-I clinical trials in Agitation (PO) in USA (NCT06546995)
- 07 May 2024 Neumora Therapeutics plans a phase Ib trial for Agitation in Alzheimer's disease in second quarter of 2024